Pamidronic acid

From Wikipedia, the free encyclopedia
  (Redirected from Pamidronate)
Jump to navigation Jump to search
Pamidronic acid
Pamidronic acid.svg
Clinical data
AHFS/ International Drug Names
MedlinePlus a601163
  • AU: B3
  • US: D (Evidence of risk)
Routes of
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability n/a
Protein binding 54%
Metabolism Nil
Elimination half-life 28 ± 7 hours
Excretion Renal
CAS Number
PubChem CID
ECHA InfoCard 100.049.897 Edit this at Wikidata
Chemical and physical data
Formula C3H11NO7P2
Molar mass 235.07 g/mol
3D model (JSmol)

Pamidronic acid (INN) or pamidronate disodium (USAN), pamidronate disodium pentahydrate (marketed as Aredia by Novartis and as Pamimed by Curacell Biotech), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.


It is used to prevent bone loss, and treat osteoporosis. It is also used to strengthen bone in Paget's disease, to prevent bone loss due to steroid use, and in certain cancers with high propensity to bone, such as multiple myeloma. Due to its ability to sequester calcium in bone, it is also used to treat high calcium levels. It is also used as an experimental treatment of the bone disorder osteogenesis imperfecta. It has been studied in the treatment of complex regional pain syndrome.[1]


Intravenous, usually 90 mg monthly. 30 mg, 60 mg, 90 mg and for hospitals, 120 mg vials are available, mixed with mannitol.

Side effects[edit]

Common side effects include bone pain, low calcium levels, nausea, and dizziness. Osteonecrosis of the jaw is a rare complication which has been associated with the use of bisphosphonates, including pamidronate.[2]

Pamidronate activates human γδ T cells in vitro and in vivo, which may lead to flu-like symptoms upon administration.


  1. ^ I. Kubalek; O. Fain; J. Paries; A. Kettaneh; M. Thomas (2001). "Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases". Rheumatology. 40 (12): 1394–1397. doi:10.1093/rheumatology/40.12.1394. PMID 11752511. 
  2. ^ Zarychanski R, Elphee E, Walton P, Johnston J (2006). "Osteonecrosis of the jaw associated with pamidronate therapy". Am J Hematol. 81 (1): 73–5. doi:10.1002/ajh.20481. PMID 16369966.